NLS Pharmaceutics Sets Shareholder Meeting for June 27
Ticker: NCEL · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, proxy-card, corporate-governance
TL;DR
NLS Pharma shareholder meeting June 27, record date June 5. Vote your shares!
AI Summary
NLS Pharmaceutics Ltd. filed a Form 6-K on June 6, 2024, to report its Notice of Meeting and Proxy Card for the Ordinary Shareholders' Meeting scheduled for June 27, 2024. Shareholders of record as of June 5, 2024, are eligible to vote.
Why It Matters
This filing informs shareholders about an upcoming meeting where important company decisions will be voted upon, impacting the company's future direction.
Risk Assessment
Risk Level: low — This is a routine filing announcing a shareholder meeting and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 27, 2024 (date) — Shareholders' Meeting date
- June 5, 2024 (date) — Record date for voting eligibility
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the Registrant's Notice of Meeting and Proxy Card for the Ordinary Shareholders' Meeting.
When is the Ordinary Shareholders' Meeting scheduled to be held?
The Ordinary Shareholders' Meeting is scheduled to be held on June 27, 2024.
Who is eligible to vote at the Shareholders' Meeting?
Shareholders of record who hold common shares of the Registrant at the close of business on June 5, 2024, will be entitled to vote.
What is the company's principal executive office address?
The company's principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
What is the Commission file number for NLS Pharmaceutics Ltd.?
The Commission file number for NLS Pharmaceutics Ltd. is 001-39957.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-06-06 17:00:03
Filing Documents
- ea0207453-6k_nlspharma.htm (6-K) — 11KB
- ea020745301ex99-1_nlspharma.htm (EX-99.1) — 45KB
- ex99-1_001.jpg (GRAPHIC) — 652KB
- ex99-1_002.jpg (GRAPHIC) — 1257KB
- 0001213900-24-050412.txt ( ) — 2687KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: June 6, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2